复方苦参注射液联合胸腺肽疗法对肿瘤患者血清中肿瘤标志物的影响

摘要

Objective:To observe the influence of composite Radix Sophora Flavescentis injection and Thymosin combination therapy on serum tumor markers in tumor patients. Methods:Forty-eight tumor patients accepted com-posite Radix Sophora Flavescentis injection 12ml/d intravenously for 5 consecutive days per month in combination with the immune regulation substances( Thymosin ). Totally CEA,AFP,CA153/CA125/CA199/CA724/CA211/CA242,NSE and SCC were measured and analyzed. Results:The levels of serum tumor markers(CEA,AFP,CA724/CA211)were significantly lower after treatment than those before treatment( p <0. 05 ) except CA153/CA125/CA199/CA242,NSE,SCC. Conclusion:Composite Radix Sophora Flavescentis injection and Thymosin combination therapy has some antitumous effect.%目的：观察复方苦参注射液联合胸腺肽对肿瘤患者血清中肿瘤标志物水平的影响。方法：分析48例接受复方苦参注射液（12ml/d，静脉滴注，连用5d/月）与免疫调节药物（胸腺肽）组合方案治疗肿瘤患者，检测治疗前后患者血清中肿瘤标志物包括癌胚抗原（CEA）、甲胎蛋白（AFP）、糖类抗原153（CA153）、糖类抗原125（CA125）、糖类抗原199（CA199）、糖类抗原724（CA724）、细胞角蛋白19片段（CA211）、神经元特异性烯醇化酶（NSE）、鳞癌相关抗原（SCC）、糖类抗原242（CA242）等的水平，分析治疗前后变化。结果：接受治疗的48例患者的肿瘤标志物（ CEA、AFP、CA724、CA211）均较用药前有显著差异，其余肿瘤标志物（ CA153、CA125、CA199、NSE、SCC、CA242）治疗前后差别不大，差异无统计学意义。结论：复方苦参注射液与免疫调节药物（胸腺肽）组合治疗能降低CEA、AFP、CA724及CA211水平，联合用药在抗肿瘤的治疗方面起到一定的作用。